GENE ONLINE|News &
Opinion
Blog

2020-10-24| Asia-PacificCOVID-19

Taiwanese Government Grants 16 Million to aid Adimmune’s COVID-19 Vaccine Trials

by Tyler Chen
Share To

By Tyler Chen

As the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia and the only PIC/S GMP manufacturer of human vaccines in Taiwan, Taiwan’s biotech company Adimmune Corporation lately acquired 458 million TWD (around 16 million USD) grant from the government to advance COVID-19 vaccine clinical trials.

 

AdimrSC-2f Under Phase 1 Trial

Adimmune’s self-developed vaccine AdimrSC-2f (SARS-COV-2) has entered Phase 1 clinical trial on August 24, and Phase 2 is expected to begin in November.

The study (NCT04522089) aims to investigate the safety and immunogenicity of AdimrSC-2f. Phase 1 of the trial includes 68 healthy subjects aged 20 to 60-year-old and breaking into 4 separate groups. Four groups will respectively be given a low, medium, high dose of AdimrSC-2f, while one group will receive a low dose of AdimrSC-2f with aluminum as an adjuvant. The trial is conducted under a randomized, single-centered setting at National Taiwan University Hospital.

If the result shows any promise, AdimrSC-2f will enter Phase 2 on November 20, enrolling at least 1,500 subjects cooperating with more hospitals. The overall study is estimated to complete on March 20, 2021.

To strengthen the manufacturing power, Adimmune, on June 9, announced the 700 million TWD investment (around 24 million USD) to expand a new production line to meet the surging needs for vaccines. The expansion is expected to complete in 2021.

Adimmune’s Partnership

Founded in 1965, Adimmune has worked with one of Japan’s largest vaccine researchers and manufacturers, Kitasato Daiichi Sankyo, obtaining the technology for tetanus vaccines, Japanese encephalitis vaccines, influenza vaccines, bird flu vaccines’ production. Moreover, Adimmune joined forces with Crucell N.V., which Johnson & Johnson acquired to establish Adimmune’s EU PIC/S GMP quality system.

Adimmune’s product line includes the Trivalent Influenza vaccine, the Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), and Tetanus toxoid, and purified Tuberculin.

Related Article: Taiwan’s TTY Biopharm Company Signs COVID-19 Vaccine Deal with BioNTech for 30 Million Doses

References
  1. http://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno%5B4%5D=6258
  2. http://www.adimmune.com.tw/news_content.php?id=229
  3. https://clinicaltrials.gov/ct2/show/NCT04522089

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
2024-01-26
JPM 2024: Taiwan’s Pharma Giant Bora Pharmaceuticals Climbing US Pharmaceutical Summit
2024-01-10
An Interview with AusBiotech CEO Lorraine Chiroiu, Highlighting Innovations and Growth in the Australian Biotech Sector
2023-12-16
LATEST
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
EVENT
Scroll to Top